AU4778293A - Non-native liver generation in an animal with impaired native liver function by cell implantation - Google Patents
Non-native liver generation in an animal with impaired native liver function by cell implantationInfo
- Publication number
- AU4778293A AU4778293A AU47782/93A AU4778293A AU4778293A AU 4778293 A AU4778293 A AU 4778293A AU 47782/93 A AU47782/93 A AU 47782/93A AU 4778293 A AU4778293 A AU 4778293A AU 4778293 A AU4778293 A AU 4778293A
- Authority
- AU
- Australia
- Prior art keywords
- native
- liver
- cells
- animal
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004185 liver Anatomy 0.000 title claims description 100
- 241001465754 Metazoa Species 0.000 title claims description 71
- 230000003908 liver function Effects 0.000 title claims description 39
- 238000002513 implantation Methods 0.000 title claims description 25
- 230000001771 impaired effect Effects 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims description 94
- 210000003494 hepatocyte Anatomy 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 44
- 108700019146 Transgenes Proteins 0.000 claims description 29
- 210000005229 liver cell Anatomy 0.000 claims description 27
- 210000001519 tissue Anatomy 0.000 claims description 25
- 208000019423 liver disease Diseases 0.000 claims description 20
- 230000001605 fetal effect Effects 0.000 claims description 17
- 210000005228 liver tissue Anatomy 0.000 claims description 15
- 230000003394 haemopoietic effect Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 210000000013 bile duct Anatomy 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 210000003014 totipotent stem cell Anatomy 0.000 claims description 6
- 206010019670 Hepatic function abnormal Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 239000008177 pharmaceutical agent Substances 0.000 claims description 5
- 210000003240 portal vein Anatomy 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 210000002434 celiac artery Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 208000027219 Deficiency disease Diseases 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 15
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 230000012010 growth Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 102000001938 Plasminogen Activators Human genes 0.000 description 6
- 108010001014 Plasminogen Activators Proteins 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 229940127126 plasminogen activator Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 2
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000013354 cell banking Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 108700017737 hepatitis B virus L Proteins 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000027739 mammary gland involution Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007772 nodular growth Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Meat, Egg Or Seafood Products (AREA)
Description
Description
Non-Native Liver Generation in an
Animal With Impaired Native Liver Function, by Cell Implantation
Technical Field
The invention relates to non-native functioning liver generation in animals with impaired native liver function, and to (transgenic) animals harboring functioning non-native livers.
Background Art
There is a current notable shortage of donor livers. In 1990, illustratively, 2, 656 liver transplants were performed, but 10 times more people died of liver disease. The treatment of liver disease by the implantation of healthy liver cells has long been envisioned as a potential solution to liver diseases. Hepatocyte transplantation could be used to treat patients with congenital hepatic enzyme deficiencies to replace liver lost through disease (e.g. viral hepatitis, alcohol-related cirrhosis or fibrosis) , or provide a temporary support system where acute liver dysfunction may be resolved by regeneration over a period of time. Hepatocyte transplantation also offers the opportunity to create animal models with human liver function. Such animals would be very useful for the study of viral infections affecting the liver (e.g. human hepatitis virus or cytomegalovirus infection) and/or test the effectiveness and safety of treatment or therapies for such infections. They would also be useful for the study of chemical (e.g. alcohol) toxicity in the human liver and chemical-induced cirrhosis and fibrosis and to test the effectiveness and safety of treatments or therapies for chemical-induced liver damage.
Historically, several methods have been pursued in an attempt to create an auxiliary liver. Transplantation of liver fragments had been carried out as early as the 1930s. However, in most cases the transplanted liver tissue either degenerated
or disappeared within a few days or weeks.
Greater success in hepatocyte transplants have been observed through the development of methods for isolating viable hepatocytes. Among these methods, the "digestion-perfusion" method of Barry and Friend (J. Cell Biol . , (1969) 41:506-520) , block perfusion (Rees and Byard, In Vitro, (1981) 17:935-941) , and injection-digestion (Woods et al, Transplantation, (1982) 3_3_:123-126) have produced good yields of viable mature hepatocytes for injection. For a review see Gupta et al, Hepatoloσv. (1992) 15:156-162.
In addition to problems in hepatocyte isolation, the method and site of implantation have been investigated for their effect on transplantation. Direct infusion of hepatocyte suspensions into the portal vein of rats has been investigated. However, contrary to initial beliefs, the portal blood supply was not found to be paramount to hepatocyte survival. Demonstrations have been made for hepatocyte growth following intramuscular injection, abdominal cavity injection, spleen, liver and kidney inoculation, and injection into celiac or renal arteries. While the above-mentioned methods have been able to produce small amounts of viable implanted hepatocytes, the resulting hepatic contribution to function has been relatively small and often temporary.
Another currently investigated approach to liver transplant resides in the implantation of new liver cells on scaffolds of biodegradable polymers that are hoped to regenerate into masses and take over at least some of the native liver's functions. Although it has been reported that with this approach liver cells on a matrix can survive and function in rats six months to a year after transplantation, implanted cell survival is low, and, in some animal trials, too much connective tissue grew into the matrix, binding tightly to the polymer and forming scar tissue preventing the liver cells from dispersing through the matrix
("Technology Review" July 1992, pp. 12, 13) .
In a different vein, transgenic animal technology has provided the means to create and analyze animal models of genetic diseases affecting virtually any organ to which transgene expression can be directed. Because of its involvement in many diseases of medical importance, the liver has been a frequent target for this type of analysis.
Among transgenes reported to be associated with liver lesions are those encoding growth hormone, which alters hepatocyte size and nuclear characteristics; oncogenes, which induce hepatic tumors; the hepatitis B virus large envelope polypeptide, which induces hepatocellular necrosis and carcinoma formation in adults; transforming growth fact a , which causes both tumors and excessive liver growth; and a variant form of α1-antitrypsin (AAT) , which reproduces some characteristics of AAT deficiency disease in humans, including neonatal and adult hepatitis.
Because of the liver's large synthetic and secretory capability, targeting transgene expression to this organ also serves as a way to determine the systemic influence of overproduction of biologically potent molecules. This approach has previously been used to study the consequences of inappropriate plasminogen activator expression in vivo by introducing into mice a transgene bearing the urokinase-type plasminogen activator (uPA) coding sequence fused to the albumin enhancer/promoter (Heckel et al. Cell (19900 j62:447-456) .
Plasminogen activators catalyze the proteolytic cleavage and activation of plasminogen to plasmin, which in turn degrades fibrin clots (Collen, D. and Lijnen, H.R. (1987) Fibrinolysis and the Control of Hematostasis. In the Molecular Basis of Blood Diseases. G. Stamatoyannopoulos, A.W. Nienhuis, P. Leder, and P.W. Majerus, eds. (Phila. : W.B. Saunders Co.) , pp. 662-688) .
uPA also has been implicated in biological processes involving tissue remodeling or destruction, including ovulation, mammary gland involution, and metastasis (Danø et al. , Adv. Cancer Res. (1985) 44:149-265; Collen and Lijnen, (1987) supra ; Saksela and Rifkin, Annu. Rev. Cell Biol . (1988) 4:93-126) .
In many transgenic founder mice the albumin-urokinase type plasminogen activator (Alb-uPA) construct directed high-level uPA expression to hepatocytes, resulting in elevated plasma uPA and fatal hemorrhaging in newborns. Two lines of Alb-uPA transgenic mice were established from surviving founder mice that expressed lower levels of uPA. In these lines, about half of the transgenic neonates bled into either the intestine or abdomen and died within four days after birth, whereas the remaining transgenic offspring appeared normal and survived. Both bleeding and non-bleeding transgenic neonates displayed marked hypofibrinogenemia and unclottable blood, and it was concluded that any injury sufficient to initiate bleeding was rapidly fatal in affected mice (Heckel et al. (1990), supra) .
A general expectation in experiments of this type is that transgene expression will be stable over time in targeted cells. Unexpectedly, surviving mice in both of the Alb-uPA lines showed a gradual decrease in the level of plasma uPA activity accompanied by a restoration of clotting function that was complete between 1 and 2 months of age (Heckel et al. , (1990) supra) . This phenomenon has been explained by a report that uPA is cytotoxic for hepatocytes and that inactivation of transgene expression by DNA rearrangement in isolated hepatocytes in Alb-uPA mice is followed by repopulation of the entire liver by cells that no longer produce uPA (Sandgren et al, Cell (1991) 6_6_:245-256) . Thus, Alb-uPA expression provides a transgenic mouse in which endogenous transgene-expressing hepatocytes have a selected disadvantage relative to hepatocytes (native or non-native) that are not expressing the transgene. In addition, the livers in these mice provide an environment for growth of
hepatocytes (native or non-native) that are not expressing the transgene. These cells grow out at the expense of transgene- expressing cells and the result is livers with apparently normal architecture.
Disclosure of the Invention
Despite progress made in the implantation and development of mature hepatocytes, present technology has not made possible the generation of a (functioning) non-native liver into an animal, particularly one with defective liver function. In humans, such technology would be useful in liver disease therapy and/or treatment. In non-human animals such technology would have considerable value, e.g. to provide models of (diseased) human liver function useful to study potential treatment and/or therapies for human liver disease.
Accordingly, one object of the invention is to provide a method of correcting defective liver function in an animal host by implanting particular non-native cells (or corresponding tissue) into the liver region of a host animal with impaired native liver function to thereby generate a functioning non-native liver in the host and correct the impaired liver function. Another object of the present invention is to provide transgenic, non-human animals (e.g. rodents such as mice) harboring a transgene that encodes a product that is disadvantageous, but not lethal, to native liver cells and thus impairs native liver function. These transgenic, non-human animals are useful as a host system for non-native (e.g. human) liver. Another object of the present invention is to provide non-human host animals that can both maintain and expand a fully-functioning non-native (e.g. human) liver tissue useful for (1) modeling liver disease, (2) liver tissue banking (e.g. maintenance and expansion of liver tissue for later analysis and re-implantation back into donors) , (3) testing pharmaceuticals for human liver toxicity in vivo, and/or (4) genetic manipulation
prior to re-implantation (i.e., hepatocyte-directed gene therapy) . Another object of the invention is to provide a method of generating a functioning non-native liver in a host animal by implanting non-native liver cells (or tissue) into a host animal with a genetically established defective liver function. Another object of the invention is to provide non-human animals harboring a functioning non-native liver. Another object of the invention is to provide a novel method for maintaining full-differentiated, full-functioning donor (e.g. human) hepatocytes in an in vivo setting for genetic manipulation prior to return to the donors . The genetic manipulation could include, for example, introducing expression vectors that direct the production of medically important proteins in the transplant recipient.
It has been discovered by the inventors that the above objects of the invention and other objects which will become apparent from the description of the invention given hereinbelow are satisfied by implanting non-native cells (e.g, fetal, neonatal or adult, non-hematopoietic liver stem, progenitor or mature cells; fetal, stem, progenitor or adult bile duct cells; endodermal (e.g. pancreas or gut) cells; (cultured) totipotent stem cells; or cultured animal cells) , or corresponding tissue, into the liver region of a host animal having impaired native liver function, such that the implanted cells (or tissue) colonize the host animal and develop therein a functioning non-native liver.
Best Mode for Carrying Out the Invention
Any animal having impaired native liver function may be used in accordance with the invention as a suitable host animal . Suitable host animals therefore include fish, fowl (e.g. chickens, ducks, geese, turkeys, etc.) , or mammals such as rodents (e.g. mice or rats) , guinea pigs, pigs, dogs, cats, rabbits, goats, sheep, horses, ruminants such as cows, monkeys, other non-human primates, as well as humans.
Impairment of native liver function in the host animal may have occurred accidentally, e.g. through disease, such as cirrhosis, hepatitis, fibrosis or a genetic liver deficiency disease such as deficiencies in Factor IX, Factor VIII, LDL receptor, or one of varied metabolic enzymes (e.g. phenylalanine hydroxylase) , or any of the other hundreds of known metabolic diseases that affect the liver.
In a preferred embodiment, the invention is applied as therapy and/or treatment to such animals, including humans, suffering from liver failure. In this context, the invention is used as an alternative to liver transplant to restore liver function.
In another embodiment, a non-native liver is generated in a non-human animal in which liver insufficiency has been induced to obtain an animal model system with a functioning non-native (e.g. human or other animal) liver. In these non-human animals, impairment of native liver function may be purposefully achieved by compromising the native hepatocyte genetically so that they are at a selective disadvantage towards implanted non-native cells (e.g. hepatocytes) .
In accordance with the invention, during normal turnover of hepatocytes, the implanted non-native hepatocytes have a proliferative advantage over the accidentally or purposely disadvantaged native hepatocytes and ultimately replace all of the native hepatocytes in the host . This provides a host harboring substantially few, if any native hepatocytes, but a functioning, substantially non-native, liver generated from the implanted non-native cells. (The liver generated is substantially non-native insofar as it is likely to comprise some non-hepatocyte cells found in the native liver and perhaps some native hepatocytes.)
Genetic inducement of liver insufficiency in a non-human
mammal may be achieved in accordance with this embodiment of the present invention with a transgenic, non-human animal harboring a transgene which encodes a product that is disadvantageous, but not immediately lethal, to native liver cells. Generally, any deleterious transgene product may be used that impairs cellular function to the extent that hepatocytes expressing the gene have a distinct growth disadvantage relative to cells that do not express a transgene (e.g. the implanted non-native hepatocytes) .
Examples of such transgene products include any type of plasminogen activator, such as an urokinase-type or tissue-type plasminogen activator, or bacterial plasminogen activators (e.g. strptokinase) or toxins such as an attenuated diphtheria toxin. Other examples of transgene products useable in accordance with this embodiment of the present invention include agents that adversely affect the metabolism or growth potential of the native liver cells. Illustrative agents are agents which compromise the ability of the native liver cells to transmit growth factor signals (e.g. with dominant and negative transgenes affecting steps in signal transduction pathway) or by producing mutant proteins that clog circulatory pathway(s) .
In an illustrative genetic inducement of liver failure, the expression of high levels of urokinase-type plasminogen activator (uPA) has been reported by the inventors to cause impaired liver function in mammals. Sandgren et al in Cell (1991) .99:245-256. Surviving transgenic animals harboring Alb-uPA are born with a liver consisting of smooth, pale to nearly white tissue, "white liver, " within which develop multiple reddish nodules which expand in size with age. The white areas represent original transgenic liver tissue while the red areas represent post-natal changes in some aspects of liver function and structure which give rise to red nodular growth. The white tissue samples express high levels of uPA mRNA whereas all samples of the red nodules lack detectable transgene expression.
This white liver tissue contains small hepatocytes with altered rough endoplasmic reticulum morphology but is neither necrotic or fibrotic. Expression of the uPA transgene appears to be deleterious to hepatocytes, but not immediately lethal. This kind of genetic impairment of native liver function provides a suitable format for establishing regenerative liver outgrowths from either donor animals (e.g. humans) or endogenous liver cells that spontaneously cease uPA transgene expression through DNA recombination and loss of all functional copies of the transgene tandem array.
In the later case, heterozygous Alb-uPA mice frequently develop regenerative liver nodules with normal reddish liver color that grow out at expense of surrounding "white" liver tissue and eventually reconstitute the liver. These "red" liver nodules are clonal outgrowth of single hepatocytes based on analysis of the transgene remnants left behind following transgene recombination. Hepatocytes that have deleted all functional transgenes, and lack detectable transgene express, acquire a selected advantage and quickly expand and replace the transgene-expressing hepatocytes in the surrounding "white tissue". An embodiment that is an extension of these observations is that non-native (e.g. human) liver cells can be transplanted into these mice (or their functional equivalent) and, as a result of their inherent growth advantage over native, transgene-expressing liver cells, they grow out to reconstitute the liver at the expense of endogenous liver cells which do die or disappear.
According to this general genetic inducement method, a transgene that encodes a product which is disadvantageous, but not immediately lethal, to the liver cells of the host animal is constructed. The resulting fusion construct is inserted using known techniques into fertilized eggs followed by implantation into pregnant or pseudopregnant females. The progeny are then bred to produce offspring which express the construct, and which
have impaired native liver function.
A variety of different non-native cells (or corresponding tissue) may be used for implantation into the host in accordance with the invention. These cells (or tissue) may be fetal, neonatal and/or adult stem, progenitor and/or mature non-hematopoietic liver cells. Preferably non-hematopoietic liver progenitor cells and more preferably non-hematopoietic liver stem cells are used. In this context, hepatocytes, which constitute about 60% of the mammalian liver, may be used as the liver cells.
The non-native hepatocytic stem cells which may be used in the invention are distinct from fetal hematopoietic stem cells. Fetal hematopoietic stem cells are precursors to the hematopoietic system, and have previously been used to generate a non-native hematopoietic system in a host.
Other non-native cells (or tissue) which may be used in accordance with the invention include (i) stem, progenitor and/or mature bile duct cells, (ii) endodermal tissue cells such as pancreas or gut cells, (iii) optionally cultured totipotent stem cells including (ES) cells or embryonic carcinoma (EC) cells, and/or (iv) cultured animal cells.
In a particularly preferred embodiment, totipotent animal stem cells are first cultured under conditions which control their differentiation, such as by using particular growth factors in the cell culture medium, and these cultured cells are then used to colonize the host animal. Totipotent animal stem cells can also (alternatively) be first treated or cultured with growth factors that enhance survival, promote replication, and/or selectively enrich for stem cells.
Animal cells (or tissue) from other sources, including but not limited to embryonic stem cells or fetal endoderm, can also
be treated by growth factors or other substances to bring about differentiation of a particular cell lineage with characteristics of hepatic stem cells. Illustratively, embryonic stem cells or embryonal carcinoma cells can be stimulated to differentiate by retinoic acid or another inducer. Subsequent differentiation in culture along the endodermal or hepatocyte cell lineage can be achieved by stimulation with growth factors and/or selection, using known techniques and materials.
In an embodiment of the present invention, the non-native cells (or tissue) may by genetically engineered (using known techniques) to produce, in vivo in the host, a physiologically effective amount of one or more medically relevant protein and then transplanted in accordance with the present invention. This technique can be used to improve hepatocyte function in an animal, e.g, by producing Factor IX, LDL receptors, phenylalanine hydroxylase, etc. or to produce proteins of systemic value, e.g. Factor VIII, adenosine deaminase, or peptide hormones.
Thus, non-native cells (or tissue) to be implanted may be isolated from a donor animal, as noted below, and optionally cultured, using known techniques. For example, in accordance with an embodiment of the invention, non-hematopoietic liver stem, progenitor and/or mature cells are first isolated from the terminal or transitional bile ductiles of a mature donor animal other than the host animal, using known techniques. In another illustrative embodiment, hepatic cells may be isolated from the donor animal using known procedures, e.g. by extraction through a biopsy needle. Alternatively, hepatic cells may be isolated from the donor animal by collagenase perfusion of the portal vein.1
The donor animal used in accordance with the invention may
^-See, e.g. , Soda et al, Blood (1984) 63., 270-276, or Claunig et al, In Vitro (1981) 17, 913-925.
be an animal of the same species or of a different species as compared to the host animal. Generally it is a different individual . The donor animal may be any animal harboring a normal functioning liver or an animal with a congenital or squired liver disease. In a preferred embodiment the donor animal is a human.
The non-native cells (or tissue) are then introduced into the host organism in a manner which provides for implantation of a sufficient number of the non-native cells into the liver region of the host animal to permit their development into a non-native liver. The present invention does not require the use of a polymeric matrix for supporting the implanted cells. Once implanted into the liver region of the host animal, the injected cells (or tissue) are subjected therein, by virtue of their location, to a variety of native biological signals to which the native liver is normally subjected and which provide for the growth and maintenance of implanted non-native liver cells in the host .
Thus, cells from a variety of sources may be used in accordance with the invention, since such cells are comprised of a mixture of cells of different degree of development (i.e., stem, progenitor and mature cells) . These mixtures contain cells having a sufficiently primitive degree of development so that, when subjected to the biological environment of the host's liver area, these cells will establish a functioning non-native liver.
Illustratively, other cells, particularly of endodermal origin, may be used to form a new liver. For example, Scarpelli et al in Laboratory Investigation (1990) 6.2:552 reported identifying cells in the pancreas of hamsters, treated with carcinogens, which have the appearance of hepatocytes. These cells and others may form functional hepatocytes when placed in the appropriate environment (e.g. a failing liver) in accordance with the present invention.
Implantation into the host animal's liver area may be achieved using different techniques. Illustratively, a suspension of from lxlO3 to lxlO7, preferably lxlO4 to lxlO6, non-native cells, optionally together with additional adjuvants to promote the transplantation of the non-native cells (i.e., substances which are known to enhance non-native cell survival and/or division2) , are administered (e.g. injected through a syringe needle) into any of several different sites where colonization of the non-native cells may be observed.
Suitable sites include the abdominal cavity, muscle tissue, kidney, pancreas, celiac artery, fat pads and/or subcutaneous area of the host animal. Preferred sites of administration in accordance with the invention, and which are preferably effectuated by injection, include the portal vein, the spleen, directly into the native liver, and the umbilical vein of the fetal host which leads to the fetal liver.
In accordance with the invention, if the host and donor are two different animals steps are taken prior to implantation to suppress potential host immune rejection of the implanted non-native cells. This may be achieved in a variety of ways, such as by treating the host animal with cyclosporin or any other material known to suppress the host's immunological system, e.g. agents that are known to selectively destroy subgroups of the immune cell population of the host, such as T-cell destroying antibodies. Alternatively, tolerance in the host can be induced by transferring non-native cells to the thymus of the host before implantation (see, Rosselt et al, Science (1990) 24_9_:1293-1295) , or cells from an animal of the same strain as the host can be used. Still further, an immunodeficient host can be used, such as inbred strains of an animal (e.g. SCID mice or nude mice) bred to act as recipients of non-native cells.
2For example, cells can be introduced together with growth factors or other substances that enhance survival, implantation, and for growth.
In an illustrative and preferred embodiment, the recipient for the non-native cells is a transgenic mouse with defective liver function, and human non-hematopoietic liver cells are used to generate the non-native liver. A suitable transgenic mouse is described by Sandgren et al in Cell, (1991) 6_6_:245-256, which is hereby incorporated by reference. The transgenic mouse described in this publication of the inventors exhibits a high expression of albumin-urokinase-type plasminogen activator (Alb-uPA) fusion construct. This mouse with impaired liver function is a good recipient for human non-hematopoietic liver cell implantation (but mice with liver impairment resulting from other causes may be used) .
The transgenic mouse with impaired liver function is injected with non-native, preferably human non-hematopoietic liver cells such that the injected human hepatocytic stem cells colonize the native liver at the expense of the endogenous "white tissue" of the transgenic mouse. The human liver cells proliferate to form nodules which ultimately reconstitute the entire native liver of the host with human hepatocytes and establish human liver function. This includes the replacement of most mouse plasma proteins with their corresponding human plasma proteins.
The resulting mouse or any other non-human host produced in accordance with the invention, is well suited for (1) modeling study of human liver function, including screening pharmaceutical agents for treating human liver disease, (2) modeling human congenital diseases affecting the liver (including those in which the cause is unknown) by implanting patient liver cells into host mice, (3) liver cell banking (e.g. maintenance and expansion of liver tissue for later analysis or re-implantation into the donor) , (4) genetic manipulation of full-functioning, full-differentiated hepatocytes for later re-implantation into donors (i.e., hepatocyte-directed gene therapy such as hepatitis virus resistant human liver cells that express antisense against
the virus) , and/or (5) modeling human liver for analysis of therapeutic agents that can promote liver regeneration.
More particularly, the present invention provides:
(i) Methods for maintaining and generating fully- functional, full-differentiated liver tissue for future analysis and therapeutic uses;
(ii) Therapeutic uses including: (a) re-implantation of healthy liver tissue into donor patients once an infectious agent or diseased tissue has been eliminated, and (b) genetic modification of donor cells and subsequent re-implantation into donor patients (e.g. hepatocyte-directed gene therapy) ;
(iii) Animal model systems with functioning, non-native liver (e.g. human hepatocytes) for the study of viral infections (e.g. human hepatitis virus or cytomegalovirus infection) and to test the effectiveness and safety of treatments or therapies for such infections;
(iv) Animal model systems with functioning, non-native
(e.g. human) liver for the study of chemical (e.g. alcohol) toxicity in the liver and chemical-induced cirrhosis and fibrosis and to test the effectiveness and safety of treatments or therapies for chemical-induced liver damage;
(v) Methods for generating non-human animal models of congenital human liver disorders (even when the cause is not known) by reconstitution of host animal livers with human liver hepatocytes collected from patients diagnosed with liver disease;
(vi) Animal model systems with functioning, non-native (e.g. human) liver which models congenital human liver disorders (e.g. , glycogen storage diseases, a, -antitrypsin deficiency, coagulation factor disorders and deficiencies) for use in testing
the effectiveness and safety of treatments and therapies;
(vii) Methods for generating non-human animals in which the liver-derived plasma proteins (which comprise >90% of the total plasma proteins) are derived from transplanted, non-native (e.g. human) liver cells;
(viii) Animal systems with a functioning, non-native (e.g. human) liver in which to generate and study normal or abnormal donor-liver derived plasma proteins;
(ix) Animal systems with a functioning, non-native (e.g. human) liver for testing the effectiveness and safety of treatments or therapies for disorders affecting donor liver-derived plasma proteins; and
(x) Systems for generating in large quantities of recombinant plasma proteins for therapeutic or diagnostic use. Hepatocytes are equipped to assemble, and appropriately modify, copious amounts of plasma proteins; thus, transplanted hepatocytes, or their genetically engineered derivatives, may be used to generate valuable donor proteins or other derived proteins.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings . It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
Claims (41)
1. A non-human animal harboring substantially no native functioning hepatocytes and a functioning substantially non- native liver generated from implanted non-native cells or tissues.
2. The non-human animal of Claim 1, wherein said substantially functioning non-native functioning liver is a human liver.
3. A primate according to Claim 1.
4. A primate according to Claim 2.
5. A mammal according to Claim 1.
6. A mammal according to Claim 2.
7. A rodent according to Claim 1.
8. A rodent according to Claim 2.
9. A non-human animal harboring a functioning substantially non-native liver, obtained by:
(i) implanting into the liver area of a non-human animal host having impaired native liver function, cells which are non-native to said non-human animal and which are at least one member selected from the group consisting of (i) non-native fetal, neonatal and adult non-hematopoietic liver stem, progenitor and mature cells, (ii) stem, progenitor and mature bile duct cells, (iii) non-native fetal, neonatal or adult stem, progenitor and mature endodermal tissue cells, (iv) totipotent stem cells, and (v) cultured animal cells, and (ii) allowing the non-native cells to develop into a functioning substantially non-native liver in said non-human animal host and thereby obtaining a non-human animal harboring substantially no native functioning hepatocytes and a functioning substantially non-native liver.
10. The non-human animal of Claim 9, wherein said non- native cells are fetal stem, progenitor or mature non- hematopoietic liver cells.
11. The non-human animal of Claim 9, wherein said non- native cells are stem, progenitor or adult bile duct cells.
12. The non-human animal of Claim 9, wherein said non- native cells are stem, progenitor or mature endodermal tissue cells.
13. The non-human animal of Claim 9, wherein said non- native cells are totipotent stem cells.
14. The non-human animal of Claim 9, wherein said animal and said non-native cells are from the same species.
15. The non-human animal of Claim 9, wherein said animal and said non-native cells are from different species.
16. The non-human animal of Claim 9, wherein said non-native cells are human cells.
17. The non-human animal of Claim 9, wherein said non-human animal is a transgenic animal harboring an albuminplasminogen activator transgene or its functional equivalent with regard to native liver function.
18. A rodent according to Claim 17.
19. A mouse according to Claim 17.
20. A non-human animal harboring substantially no native functioning hepatocytes and a functioning substantially non- native liver, obtained by implanting into the liver area of a non-human animal host suffering from impaired native liver function, non-native fetal, neonatal or adult stem, progenitor or mature non-hematopoietic liver cells and allowing said non- native cells to develop into a non-native liver in said non-human animal host.
21. A method for restoring liver function in a human host suffering from impaired native liver function, comprising implanting into the liver area of said human, fetal, neonatal or adult human non-hematopoietic liver stem, progenitor or mature cells which are non-native to said human host, and allowing said non-native cells to develop into a functioning non-native human liver in said human host.
22. The method of Claim 21, wherein said human host suffering from impaired native liver function has been diagnosed as suffering from cirrhosis or fibrosis of the liver.
23. The method of Claim 21, wherein said human host suffering from impaired native liver function has been diagnosed as suffering from hepatitis.
24. The method of Claim 21, wherein said human host suffering from impaired native liver function has been diagnosed as suffering from a genetic deficiency disease causing said impaired native liver function.
25. The method of Claim 21, wherein said human host suffering from impaired native liver function has suffered a trauma causing said defective liver function.
26. The method of Claim 21, wherein said implantation is achieved by injecting said non-native cells into the portal vein of said human host suffering from impaired native liver function.
27. The method of Claim 21, wherein said implantation is achieved by injecting said non-native cells into the spleen of said human host suffering from impaired native liver function.
28. The method of Claim 21, wherein said implantation is achieved by injecting said non-native cells into the liver of said human host suffering from impaired native liver function.
29. The method of Claim 21, wherein said implantation is achieved by injecting said non-native cells into the celiac artery of said human host suffering from impaired native liver function.
30. A method of restoring liver function in an animal with impaired liver function, said method comprising:
(a) implanting into the liver area of a host animal in need of restoration of liver function, cells which are non-native to said host animal and which are at least one member selected from the group consisting of (i) fetal, neonatal and adult non-hematopoietic liver stem, progenitor and mature cells, (ii) stem, progenitor and adult bile duct Cells, (iii) fetal, neonatal and adult stem, progenitor and mature endodermal tissue cells, and (iv) totipotent stem cells, and (v) cultured animal cells; and
(b) allowing said non-native cells to develop into a functioning non-native liver in said host animal .
31. The method of Claim 30, wherein said implantation is achieved by injecting said non-native cells into the portal vein, spleen, liver, or celiac artery, of said host animal.
32. A method for obtaining an animal with a functioning non-native liver, said method comprising:
(a) implanting into a host animal with impaired native liver function, cells which are non-native to said host animal and which are least one member selected from the group consisting of (i) fetal, neonatal and adult non-hematopoietic liver stem, progenitor and mature cells, (ii) stem, progenitor and adult bile duct cells, (iii) fetal, neonatal and adult stem, progenitor and mature endodermal tissue cells, (iv) totipotent stem cells, and (v) cultured animal cells; and (b) allowing said non-native cells in said host to develop into a functioning non-native liver.
33. The method of Claim 34, wherein said host animal is a transgenic animal harboring a transgene which compromises native hepatocytes.
34. A method for screening a pharmaceutical agent for treatment or therapy of a human liver disorder or disease comprising using the animal of Claim 2.
35. A method for screening a pharmaceutical agent for treatment or therapy of a human liver disorders or disease comprising using the primate of Claim 4.
36. A method for screening a pharmaceutical agent for treatment or therapy of a human liver disorder or disease comprising using the mammal of Claim 6.
37. A method for screening a pharmaceutical agent for treatment or therapy of a human liver disorder or disease comprising using the rodent of Claim 8.
38. A method of using the animal of Claim 1, comprising using said animal for maintaining and generating fully- functional, fully-differentiated liver tissue for future analysis or therapeutic use.
39. A method of using the animal of Claim 9, wherein said animal is used for maintaining and generating fully-functional, fully-differentiated liver tissue for future analysis or therapeutic use.
40. The method of Claim 39, wherein said therapeutic use comprises: the reimplantation of healthy liver tissue into a donor patient from whom said cells which were non-native to said non-human animal were obtained, once an infectious agent or disease tissue has been eliminated from said donor patient.
41. A method for hepatocyte-directed gene therapy, comprising obtaining hepatocytes from a donor animal, genetically modifying said cells to enable them to produce a physiologically effective amount of at least one medically relevant protein, implanting said genetically modified cells into the non-human animal of Claim 1 to generate fully-functional, fully-differentiated and genetically modified liver tissue, and reimplanting said generated liver tissue into said donor animal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91805092A | 1992-07-24 | 1992-07-24 | |
| US918050 | 1992-07-24 | ||
| PCT/US1993/006830 WO1994002601A1 (en) | 1992-07-24 | 1993-07-23 | Non-native liver generation in an animal with impaired native liver function by cell implantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4778293A true AU4778293A (en) | 1994-02-14 |
| AU676194B2 AU676194B2 (en) | 1997-03-06 |
Family
ID=25439709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU47782/93A Ceased AU676194B2 (en) | 1992-07-24 | 1993-07-23 | Non-native liver generation in an animal with impaired native liver function by cell implantation |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0652949A4 (en) |
| JP (1) | JPH07509363A (en) |
| AU (1) | AU676194B2 (en) |
| CA (1) | CA2140785A1 (en) |
| IL (1) | IL106368A0 (en) |
| WO (1) | WO1994002601A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008598A1 (en) * | 1992-10-09 | 1994-04-28 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
| US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US5980886A (en) * | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
| AU6222996A (en) * | 1995-06-07 | 1996-12-30 | Novartis Ag | Human hepatocellular tissue in chimeric immunocompromised an imals |
| US6034297A (en) * | 1997-09-26 | 2000-03-07 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis C virus |
| US6132708A (en) * | 1997-10-10 | 2000-10-17 | Oregon Health Sciences University | Liver regeneration using pancreas cells |
| US6864402B1 (en) | 1998-09-18 | 2005-03-08 | Albert Einstein College Of Medicine Of Yeshiva University | Chronic hepatitis virus infection and clonal hepatocellular carcinoma in mouse repopulated livers |
| WO2000040083A1 (en) * | 1999-01-05 | 2000-07-13 | Surrogen, Inc. | Chimeric animal with engrafted xenogeneic tissue and method for producing same |
| US6525242B1 (en) | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
| US6995299B2 (en) | 1999-11-02 | 2006-02-07 | University Of Connecticut | Propagation of human hepatocytes in non-human animals |
| US6509514B1 (en) * | 2000-03-17 | 2003-01-21 | Kmt Hepatech, Inc. | Chimeric animal model susceptible to human hepatitis C virus infection |
| WO2001087059A1 (en) * | 2000-05-19 | 2001-11-22 | Japan Science And Technology Corporation | Chimeric animal |
| JP4907843B2 (en) * | 2002-03-25 | 2012-04-04 | 公益財団法人ひろしま産業振興機構 | Human hepatocyte proliferation method and human hepatocyte acquisition method |
| WO2004006664A1 (en) * | 2002-07-16 | 2004-01-22 | Japan Science And Technology Agency | Model animal having noncancerous liver tissue transplanted therein and method of constructing the same |
| WO2006023593A2 (en) | 2004-08-20 | 2006-03-02 | Kmt Hepatech, Inc. | Malarial animal model having a chimeric human liver |
| JP4854509B2 (en) * | 2004-08-20 | 2012-01-18 | 積水メディカル株式会社 | Methods for predicting liver metabolism and liver function of drugs in humans |
| US11172657B2 (en) | 2017-09-19 | 2021-11-16 | Pormedtec Co., Ltd. | Method for developing organ that lacks specific functional cell |
-
1993
- 1993-07-16 IL IL106368A patent/IL106368A0/en unknown
- 1993-07-23 JP JP6504654A patent/JPH07509363A/en active Pending
- 1993-07-23 CA CA002140785A patent/CA2140785A1/en not_active Abandoned
- 1993-07-23 AU AU47782/93A patent/AU676194B2/en not_active Ceased
- 1993-07-23 EP EP93918276A patent/EP0652949A4/en not_active Withdrawn
- 1993-07-23 WO PCT/US1993/006830 patent/WO1994002601A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0652949A4 (en) | 1996-08-21 |
| WO1994002601A1 (en) | 1994-02-03 |
| CA2140785A1 (en) | 1994-02-03 |
| JPH07509363A (en) | 1995-10-19 |
| EP0652949A1 (en) | 1995-05-17 |
| AU676194B2 (en) | 1997-03-06 |
| IL106368A0 (en) | 1993-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU676194B2 (en) | Non-native liver generation in an animal with impaired native liver function by cell implantation | |
| AU2010200016B2 (en) | Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells | |
| CN102388127B (en) | Lung tissue engineered | |
| Gupta et al. | Hepatocyte transplantation: back to the future | |
| Demetriou et al. | Replacement of liver function in rats by transplantation of microcarrier-attached hepatocytes | |
| Ponder | Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies | |
| Carpenter et al. | Generation and Transplantation of EGF-Responsive Neural Stem Cells Derived from GFAP–hNGF Transgenic Mice | |
| Adigbli et al. | Humanization of immunodeficient animals for the modeling of transplantation, graft versus host disease, and regenerative medicine | |
| Shull et al. | Myoblast gene therapy in canine mucopolysaccharidosis I: Abrogation by an immune response to α-L-iduronidase | |
| JPH09509821A (en) | Delivery of gene products via mesangial cells | |
| Kobayashi et al. | Organ fabrication using pigs as an in vivo bioreactor | |
| JP4906059B2 (en) | Screening method for human platelet number regulator | |
| US6132708A (en) | Liver regeneration using pancreas cells | |
| US7485293B1 (en) | Method for inhibiting transplant rejection | |
| JP2001518934A (en) | Bone marrow as a transplant site | |
| US20080104720A1 (en) | Animal Models for Cell Therapy and Cell Based Gene Therapy | |
| JP5737821B2 (en) | Hemophilia B therapeutic agent and method for producing the same | |
| CN117694305A (en) | Method for producing genetically modified mouse, human liver and human liver cell | |
| Adigbli et al. | Transplantation Publish Ahead of Print | |
| Edwards | The Role of Bone Marrow-Derived Progenitor Cells in Pancreatic Cancer | |
| Suckow et al. | Tissue distribution of fetal liver cells following in utero transplantation in mice | |
| JP2005118005A (en) | Liver-accumulating cell | |
| WO1996001053A1 (en) | Methods of preventing graft versus host disease and transplantation rejection | |
| Braun | Cell biology of hepatic repopulation in diseased liver |